| Document |
Document Title |
|
WO/2005/092890A2 |
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nic...
|
|
WO/2005/092889A1 |
A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt...
|
|
WO/2005/090341A1 |
Compounds of Formula (I) processes for preparing them, pharmaceutical compositions comprising them. The use of compounds of formula (I) for hyperproliferative diseases, e.g. cancer as well as autoimmune diseases and heart diseases.
|
|
WO2005051917A9 |
The invention relates to novel derivatives of general formula (I), wherein A, if present, is an alkyl radical (C1-C6), an alkenyl radical (C3-C6), an alkynyl radical (C3-C6), a cycloalkyl radical (C3-C7), a cycloalkenyl radical (C5-C7), ...
|
|
WO/2005/090342A1 |
Compounds of formula (1) wherein the different substituents and/or radicals have the values defined in the claims. The invention also relates to a process for the preparation of said compounds, to pharmaceutical compositions comprising t...
|
|
WO/2005/087231A1 |
A novel process for producing a composition containing either solifenacin or a salt thereof; and a composition containing either solifenacin or a salt thereof obtained by the production process, which contains a solifenacin compound havi...
|
|
WO/2005/087236A1 |
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
|
|
WO/2005/082874A1 |
It is intended to provide a drug useful as a remedy and a preventive for hyperlipemia; a drug also useful as a remedy and a preventive for liver disorders accompanying bile stasis, in particular, primary biliary cirrhosis, primary sclero...
|
|
WO/2005/077899A2 |
Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, Xa and Xb are C, CH, or N, as defined herein, and Rx is an optional substituent. Compounds and compositions of formula (I)...
|
|
WO/2005/077914A1 |
The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating &agr 4 integrin mediated disorders. More particularly, the pyridazinon...
|
|
WO/2005/077915A1 |
The present invention relates to certain novel compounds of Formula (I): Formula (I) methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of integrin mediated disorders.
|
|
WO/2005/075474A1 |
A composition comprising solifenacin succinate with the content of impurities reduced, which can be used as a pharmaceutical primary material. This composition comprising solifenacin succinate is especially featured by reduction of the c...
|
|
WO/2005/075473A1 |
This invention relates to an improved process for the preparation of (2S,3S)- 2-benzhydryl-N-(5-tent-butyl-2-methoxybenzyl)quinuclidin-3-a
mine, (hereinafter 'compound of Formula I') and its pharmaceutically acceptable salts. In partic...
|
|
WO/2005/072132A2 |
Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and h...
|
|
WO/2005/070898A1 |
The invention relates to substituted N-cyclohexyl heterocycles as well as the physiologically acceptable salts and physiologically functional derivatives thereof, methods for the production thereof, and the use thereof as medicaments. Di...
|
|
WO/2005/068461A1 |
The subject invention provides stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited t...
|
|
WO/2005/066167A2 |
Compounds of formula (I) or (II) , or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, wherein: A and G are each independently N or N+-O-; m and n are each independently 0, 1, or 2; X1 and X3 are each independently...
|
|
WO/2005/066163A2 |
This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
|
|
WO/2005/066166A2 |
Compounds of formula (I); wherein A is N or N+-O-; n is 0, 1, or 2; Y is O, S, -NH-, and -N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membered aromatic rings with a -NR8R9 group, as defined herein. The compounds are u...
|
|
WO/2005/066168A1 |
Compounds of formula (I) wherein n1 is 0, 1, or 2; n2 is 0, 1, or 2; X is a bond, O, S, or NR1; and Ar1 is a 5-membered aromatic ring, 6-membered aromatic ring, or a fused bicycloheterocycle. The compounds are useful in treating conditio...
|
|
WO/2005/061495A1 |
Compounds of formula (I), wherein D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of ps...
|
|
WO/2005/061494A1 |
Compounds of formula (I), wherein D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of ps...
|
|
WO/2005/056549A1 |
Etoposide analogs with improved water-solubility such as 4'-O-Demethyl-4'-(N', N'-dimethyl-glycyl)-4β-(4'-nitroanilino)-4-desoxy-podophyll
otoxin (8) and 4'-O-Demethyl-4'-(N', N'-dimethyl-glycyl)-4β-(4'-fluoroanilino)-4-desoxy-podophyl...
|
|
WO/2005/053663A2 |
Selective norepinephrine reuptake inhibitors are used to treat cognitive failure.
|
|
WO/2005/049611A1 |
Compounds of formula I: wherein A and R1 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and...
|
|
WO/2005/049612A1 |
Compounds of formula I: wherein A and R1 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and...
|
|
WO/2005/046590A2 |
A method of synthesizing a substituted or unsubstituted 4-amino-3-benzimidazolyl quinolinone compound includes reacting a first compound having the formula I with a second compound having the formula II in a suitable solvent in the prese...
|
|
WO/2005/047244A2 |
Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically ...
|
|
WO/2005/046589A2 |
A lacate salt of a compound of Formula: (I) or a tautomer of the compound, wherein Formula (I) has the following structure and R1-R9 and R12-R14 are as defined herein.
|
|
WO/2005/047230A1 |
The present invention relates to bis-cationic compounds comprising quaternary ammonium groups and/or quaternary phosphonium groups. The invention also relates to the use of bis-cationic compounds as Phospholipase B inhibitors and the use...
|
|
WO/2005/042529A1 |
The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful &agr 4 integrin receptor antagonists and, in particular, &agr 4β1 and &agr 4β7 inte...
|
|
WO/2005/042538A1 |
Compounds of formula (I): and pharmaceutically-acceptable salts thereof, wherein: Ar is a moiety of formula (II) or (III): and A, B, and R1 are as defined in the specification, compositions containing such compounds and the use of such c...
|
|
WO/2005/042533A2 |
A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X1 and X2 each is independently lower alkylene; X3 is =CH2, =CHF or =CF2; R1 is substituent, R2 and R3 each is independently H or lower alkyl; n is 0, ...
|
|
WO/2005/035507A2 |
Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R2, G, G', and G' represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Ph...
|
|
WO/2005/032548A1 |
New substituted benz-azole compounds of formula (I), compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with ...
|
|
WO/2005/021495A2 |
Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formulae (I), and (II) as well as isomers of these formulae.
|
|
WO/2005/019211A2 |
The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at le...
|
|
WO/2005/016909A1 |
This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
|
|
WO/2005/016923A1 |
This invention relates to novel quinuclidine derivatives represented by Formula (II) wherein represents an optional double bond; n is 1, 2 or 3; X represents a linker selected from -O-, -O-CH2-, -O-CH2-CH2-, -S-, -SO-, -SO2-, -CH2-, -S-C...
|
|
WO/2005/014517A2 |
The present invention pertains to compounds of formula (I) wherein X is O, NH, N(C1-4)alkyl, CO or CHOH, Y is CH or N, A and B are each hydrogen or together form a second bond between the carbon atoms to which they are attached, R1 is hy...
|
|
WO/2005/011675A1 |
Chemical agents of the general formula (1) and (11), such as derivatives of 3-hydroxy-pyrrole containing hydroxamic acid, and including salts thereof, that modulate levels of gene expression in cellular systems, including cancer cells, a...
|
|
WO/2005/012299A1 |
The invention relates to N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improvement in cognition, concentration power, learning power and/...
|
|
WO/2005/012256A1 |
The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and gl...
|
|
WO/2005/009928A2 |
The present disclosure provides methods of synthesizing alkylating agents and methods of use.
|
|
WO/2005/007628A1 |
The invention provides for compounds of formula (I); wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive d...
|
|
WO/2005/007094A2 |
Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/...
|
|
WO/2005/007111A2 |
The invention provides for compounds of formula (I), wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive d...
|
|
WO/2005/000305A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dop...
|
|
WO/2005/000250A2 |
The present invention relates to radiolabelled compounds particularly 1-azabicyclo [2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic ...
|
|
WO/2004/113277A2 |
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+ related disease.
|
